ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Microbiology >Integrase Inhibitors >Dolutegravir sodium

Dolutegravir sodium

Dolutegravir sodium Structure
CAS No.
1051375-19-9
Chemical Name:
Dolutegravir sodium
Synonyms
DOLUTEGRAVIR SODIUM;Dolutegravi Sodium;Dolutegravir sodiuM salt;GSK1349572 sodiuM salt USP/EP/BP;Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate;158439;GSK 1349572A;Dulutevir sodium;Dulutewei sodium salt;GSK1349572 sodiuM salt
CBNumber:
CB52646573
Molecular Formula:
C20H20F2N3NaO5
Molecular Weight:
443.38
MOL File:
1051375-19-9.mol
Modify Date:
2024/5/8 15:48:26

Dolutegravir sodium Properties

Melting point >300oC
storage temp. Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility DMSO (Slightly, Heated), Methanol (Slightly, Heated)
form Solid
color White to Green
Stability Hygroscopic
InChIKey FWLDGCYHMZPGGI-SBBUJZKLNA-N
SMILES O=C1N2[C@@H](CCO[C@@]2([H])CN2C=C(C(=O)NCC3C=CC(F)=CC=3F)C(=O)C(O)=C12)C.[NaH] |&1:3,7,r|

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS09
Signal word  Warning
Hazard statements  H400-H410
Precautionary statements  P273-P391-P501-P273-P391-P501

Dolutegravir sodium Chemical Properties,Uses,Production

Description

Dolutegravir, also known as DTG or dolutegravir sodium, is an antiretroviral therapy drug used to treat HIV infection. It belongs to the Integrase Strand Transfer inhibitor (INSTi) class of drugs and was fast-tracked by the FDA in February 2012. GlaxoSmithKline developed and markets dolutegravir sodium (Tivicay), which received FDA approval in August 2013 as a novel integrase inhibitor for HIV treatment, including adults undergoing their first treatment as well as those who have been treated with other integrase transfer strand inhibiting agents.

Uses

Dolutegravir, a second-generation HIV-1 integrase strand transfer inhibitor, is commonly used along with other medications to manage HIV infection. Its potency in inhibiting HIV replication has been demonstrated in various cell types infected with a self-inactivating PHIV lentiviral vector, including peripheral blood mononuclear cells (PBMCs), MT-4 cells, and CIP4 cells.

Definition

ChEBI: Dolutegravir sodium is an organic sodium salt that is the monosodium salt of dolutegravir. Used for treatment of HIV-1. It has a role as a HIV-1 integrase inhibitor. It contains a dolutegravir(1-).

Side effects

Dolutegravir, an HIV medication, can lead to a variety of side effects. While some can be serious, many, such as nausea or sporadic dizziness, can be effectively managed. Dolutegravir may also cause alterations in your immune system, resulting in a condition known as immune reconstitution inflammatory syndrome (IRIS).
clinicalinfo.hiv.gov/en/drugs/dolutegravir/patient

Synthesis

The most likely process-scale synthesis of dolutegravir sodium, began with benzyl protection and alkylation of pyrone 46 with benzaldehyde, yielding alcohol 47 in 74% over 2 steps. Alcohol mesylation and in situ elimination provided the styrenyl olefin 48 in 94% yield, which further underwent an oxidative cleavage of the olefin to generate 49 by sequential addition of RuCl3/NaIO4 and NaClO2 (56% overall yield). Treatment of pyranone 49 with 3-amino-propane-2-diol (50) in ethanol at elevated temperatures delivered the corresponding pyridinone in 83% yield, and this was followed by esterification and sodium periodate-mediated diol cleavage to furnish intermediate 51 in 71% overall yield across the two-step sequence. l Next, the key ring-forming step in the synthesis of dolutegravir sodium consisted of cyclization of 51 with (R)-3- amino-butan-1-ol, a process which relies on substrate control to provide the desired tricyclic carbamoylpyridone system 52 in high stereoselectivity (20/1 in favor of the desired isomer).51 Previously, cyclization of systems such as 51 with unsubstituted amino alcohols were found to yield a mixture of diastereomeric products, therefore indicating the pivotal role of the chiral amino alcohol in influencing stereochemical bias during the overall cyclization step. In practice, reaction of 51 with (R)-3-amino-butan-1-ol at 90 ?? led to isolation of a single cyclization product 52, after recrystallization from EtOAc. From 52, N-bromosuccinimide (NBS) bromination and subsequent treatment with amine 53 under palladium-catalyzed amidocarbonylative conditions led to amide 54 in 75% yield over 2 steps. Finally, removal of the benzyl group and subsequent crystallization using sodium hydroxide in water and ethanol provided dolutegravir sodium (VII) in 99% yield.

Synthesis_1051375-19-9

Global( 226)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
ALMELO PRIVATE LIMITED +91-9100991345 +91-8500807769 Telangana, India 114 58 Inquiry
SUJALAM CHEMICALS +91-9422560788 +91-9422560788 Maharashtra, India 42 58 Inquiry
Honour Lab Limited +919845977466 Telangana, India 164 58 Inquiry
Mangalam Drugs and Organics Ltd +91-2222616300 +91-2222616200 Maharashtra, India 37 58 Inquiry
VIVIN DRUGS AND PHARMACEUTICALS LTD +91-22670456625 +91-224067045635 Telangana, India 22 58 Inquiry
Amara Labs Pvt Ltd +91-9553279972 +91-9100091565 Hyderabad, India 42 58 Inquiry
Humble Healthcare Limited +91-9720093000 +91-8006400378 Uttar Pradesh, India 141 58 Inquiry
Arene Lifesciences Limited +91-9849847907 +91-8455241148 Telangana, India 55 58 Inquiry
Mylan Laboratories Ltd +91-4023550543 +91-4030866666 Telangana, India 150 58 Inquiry
Apicore Pharmaceuticals Pvt Ltd +91-2662267177 +91-2662267166 Gujarat, India 181 58 Inquiry

Related articles

GSK1349572 sodiuM salt GSK 1349572A Dolutegravir SodiuM ( API) Dolutegravir sodium(GSK1349572) (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide sodium salt (1:1) (4R,12AS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyri 158439 Dolutegravir Sodium (GSK-1349572A) (4r,12as)-9-[(2,4-difluorophenyl)methylcarbamoyl]-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2h-pyrido[5,6]pyrazino[2,6-b][1,3]oxazin-7-olate DOLUTEGRAVIR SODIUM Dolutegravir sodiuM salt Dolutegravi Sodium Dulutewei sodium salt Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate GSK1349572 sodiuM salt USP/EP/BP Dulutevir sodium Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate GSK1349572|||GSK-1349572A 1051375-19-9 C20H18F2N3NaO5 C20H18F2N3O5Na C20H19F2N3NaO5 Inhibitors HIV-1 integrase inhibitor 1051375-19-9